2022 International Bladder Cancer Network

Viewing 1-20 of 42 articles

IBCN 2022: Epigenomic Mapping Identifies a Super-Enhancer Repertoire That Regulates Bladder Cancer Cell Identity Through Distinct Transcription Factor Networks

IBCN 2022: Automated, Cell-Based Measurements Can Define Low-Grade and High-Grade Noninvasive Papillary Urothelial Carcinoma and Predict Time to Recurrence

IBCN 2022: Validation of a GATA2 Methylation and FGFR3 Mutation Assay To Predict Progression in BCG-Treated High-Risk Non-Muscle-Invasive Bladder Cancer

IBCN 2022: Proteomic Profiling of Muscle Invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy

IBCN 2022: Novel Clinic-Genomic Score Predicting Outcomes With Platinum-Based Chemotherapy in Patients With Treatment Naïve, Metastatic Urothelial Cancer

IBCN 2022: IBCN Biobank Consortium - Overcoming Barriers in Data Sharing

IBCN 2022: Genome-Wide Circulating Tumor DNA for Monitoring Treatment Response and Metastatic Relapse in Bladder Cancer

IBCN 2022: Clinical Application of CG0070 in Bladder Cancer: Lessons Learned

IBCN 2022: ICAM-1 Targeted Immunotherapeutic Coxsackievirus A21 (CVA21) as an Oncolytic Agent for Non-Muscle Invasive Bladder Cancer

IBCN 2022: Oncolytic Virotherapy

IBCN 2022: General Data Protection Regulation (GDPR) and Data Sharing

IBCN 2022: The Cancer Genome Atlas (TCGA) – Lessons Learned

IBCN 2022: The UROMOL Project, Molecular Characteristics of NMIBC to Identify and Validate Biomarkers of Recurrence and Progression

IBCN 2022: Targeting HLA-E and NKG2A for the Treatment of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

IBCN 2022: Spatial Prioritization of Cellular Interactions in the Tumor Microenvironment

IBCN 2022: ATM Loss and Therapeutic Vulnerabilities in Bladder Cancer

IBCN 2022: NPEPPS Can Be Targeted To Overcome Cisplatin Resistance in Patient-Derived Bladder Cancer Tumoroids

IBCN 2022: Immunotherapy of Bladder Cancer Through STING Activation Empowered by Urease-Nanomotor Nanoparticle System

IBCN 2022: Tumor Cell-Intrinsic Expression of FGFR3 Drives Anti-PD-1 Immunotherapy Resistance in a Murine Bladder Cancer Model

IBCN 2022: The Accuracy of Cystoscopy in Predicting Detrusor Invasion in Newly Diagnosed Bladder Cancer Patients

1
2
3